Revisiting the HIF switch in the tumor and its immune microenvironment.

May combine two claims.

Hypoxia can drive dedifferentiation of surgically derived GBM cells toward a stem-like phenotype at least partly via HIF-2α, not HIF-1α, since HIF-2α knockdown in glioma stem cells reduces tumor initiation in vivo.

“Hypoxia can induce dedifferentiation of surgically-derived GBM tumor cells to a more stem-like phenotype driven at least in part, through activation of HIF-2α, but not HIF-1α, as knockdown of HIF-2α (but not HIF-1α) in glioma stem cells inhibits their tumor initiating potential in vivo [45–48].”

• cites [45] sourceDisputed

  The section “HIF2α Promotes a Cancer Stem Cell State” supports the claim that HIF2α can promote a stem-like phenotype in non-stem glioblastoma cells. But “The Role of Hypoxia Inducible Factors in Cancer Stem Cell Self-Renewal and Tumor Growth” says stem cells with either HIF1α or HIF2α targeted failed to initiate tumors on xenotransplantation, contrary to the claim that HIF1α knockdown did not inhibit tumor initiation. Page numbers are unavailable in our copy. (LLM, conf=0.91)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [46] sourceNot checked — no full text of the source
• cites [47] sourceNot checked — no full text of the source
• cites [48] sourceNot checked — no full text of the source

May combine two claims.

HIF-1α, but not HIF-2α, has also been shown to increase self-renewal of stem-like U251 and U87 GBM cells and inhibit differentiation, suggesting the HIF-α isoform dependency for maintaining GBM stem-like cells may be cell type specific.

“However, HIF-1α (but not HIF-2α) has also been shown to enhance the self-renewal activity of stem-like U251 and U87 GBM cells and to inhibit the induction of differentiation suggesting that the HIF-α isoform dependency involved in the hypoxia-mediated maintenance of GBM stem-like cells may be cell type specific [50–52].”

• cites [50] sourcePartly supported

  The Results section, “Influence of HIF1α on neurosphere formation” (page unavailable), reports that silencing HIF1α in differentiated U87 cells reduced hypoxia-induced neurosphere formation and stem-cell markers. This supports a role for HIF1α in acquiring stem-like features, but not the claimed self-renewal of already stem-like U87 and U251 cells. The cited passages do not establish inhibited differentiation or a comparison with HIF2α, so they do not substantiate the proposed isoform-specific difference. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [51] sourceDisputed

  The Introduction (p. 2) says HIF-2α appears to be the primary driver of hypoxia-induced dedifferentiation, contrary to the claim’s HIF-1α-but-not-HIF-2α attribution. The Summary (p. 2) likewise links the stem-like glioma phenotype to HIF-2α stabilization. Although the paper uses U251MG cells, the cited passages do not report the claimed self-renewal and differentiation result in stem-like U251 and U87 cells. (LLM, conf=0.86)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [52] sourceCould not verify

  In the HIF2α in GBM discussion (page not supplied), the review reports HIF2α—not HIF1α—upregulation in glioma stem cells and reduced tumorsphere formation after HIF2α knockdown. It does not address HIF1α-driven self-renewal or inhibited differentiation in stem-like U251 and U87 cells. Those broader findings do not rule out the cell-type-specific result claimed here; searches for U251, U87, self-renewal and differentiation found no passage verifying it. (LLM, conf=0.70)

  Experimental — accuracy not yet measured

May combine two claims.

PT2399 inhibited tumor growth in most human patient-derived xenografts and had stronger anti-tumor activity than sunitinib.

“PT2399 suppressed tumor growth in most human patient derived xenografts (PDXs) with greater anti-tumor activity than that of the tyrosine kinase inhibitor (TKI), sunitinib [22].”

• cites [22] sourceSupported

May combine two claims.

Under low oxygen, HIF-α subunits become stable, move to the nucleus, pair with HIF-1β, and bind hypoxia response elements in target gene regulatory regions.

“In hypoxia, HIF-α subunits are stabilized and translocate to the nucleus where they form heterodimers with HIF-1β, and bind the hypoxia response element (HRE) within regulatory elements of target genes (Fig. 1B) [3].”

• cites [3] sourcePartly supported

  The Abstract (page not provided) says hypoxia activates HIF-1, that HIF-1 contains α and β subunits, and that it binds promoter/enhancer-linked HIF sites in hypoxia-responsive genes. The Results (page not provided) find hypoxia-induced HIF-1α-containing DNA-binding complexes in nuclear extracts. Our copy does not establish that hypoxia stabilizes HIF-α subunits or causes them to translocate to the nucleus. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

HIF-1α mainly controls genes for anaerobic glycolysis and cell death, whereas HIF-2α primarily regulates erythropoietin synthesis and genes linked to tumor stemness or pluripotency.

“Furthermore, genes regulating anerobic glycolysis or cell death appear to be predominantly controlled by HIF-1α, whereas genes regulating erythropoietin synthesis (EPO) and tumor stemness or pluripotency are primarily HIF-2α-regulated (Fig. 2A) [10].”

• cites [10] sourcePartly supported

  The Discussion (page not supplied) supports HIF-1α-specific regulation of glycolytic genes in the cell lines studied. The paper also says HIF-2α can activate an erythropoietin reporter, but it does not establish that erythropoietin is primarily HIF-2α-regulated. Its discussion of cell death concerns the consequences of impaired glycolysis, not predominant regulation of cell-death genes; the passages found do not address HIF-2α regulation of tumor stemness or pluripotency genes. (LLM, conf=0.89)

  Experimental — accuracy not yet measured

May combine two claims.

HIF-1α is detected by IHC in most ccRCC cases, and high HIF-1α expression is associated with poor survival, which conflicts with a tumor suppressor role.

“Nevertheless, HIF-1α has been detected by immunohistochemistry (IHC) in most ccRCC cases, and high HIF-1α expression was associated with poor survival in ccRCC, which is again inconsistent with a tumor suppressor role [34].”

• cites [34] sourceCould not verify

  The supplied Neuroblastoma and Medulloblastoma passages discuss MYCN and other developmental cancer mechanisms, not HIF-1α in ccRCC. Further searches for HIF-1α, immunohistochemistry, poor survival, and clear-cell renal carcinoma found no passage in our copy addressing the claim. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

In vitro HIF-1α knockdown in the same genetic context did not affect in vitro or in vivo allograft growth, highlighting the importance of physiological context for HIF isoform contributions to ccRCC.

“Strikingly, in vitro HIF-1α knockdown within this same genetic context had no effect on in vitro or in vivo allograft growth, underscoring the importance of physiological context in determining the contribution of the HIF isoforms to ccRCC development and progression [33].”

• cites [33] sourceCould not verify

  The Results describe HIF-1α expression in ccRCC cells and tumor-associated macrophages, and the Discussion considers how the tumor microenvironment affects that expression. Neither section reports HIF-1α knockdown or its effects on in vitro growth or in vivo allograft growth (searched: knockdown, allograft). (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

PT2399 inhibited growth of 786-0 and A498 xenografts but not UMRC2 or 769P cells, even though it inhibited HIF-2α-dependent transcription in all with similar IC50s.

“Indeed, PT2399 significantly inhibited the growth of 786–0 and A498 tumor xenografts, but did not inhibit the growth of UMRC2 or 769P cells despite inhibiting HIF-2α-dependent transcription in these cells with IC50s comparable to those seen in 786-O and A498 cells [29].”

• cites [29] sourceCould not verify

  The Discussion (page unavailable) mentions HIF-2-inhibition-resistant patient-derived xenografts, but does not report PT2399 results for 786-O, A498, UMRC2, or 769P. Searches for PT2399, the cell lines, and comparable transcriptional IC50s found no passage addressing the claimed comparison. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

In vitro PT2385 treatment of the same PDX line did not affect viability or proliferation, suggesting the survival benefit may come from inhibiting tumor features needed for in vivo progression.

“Intriguingly, PT2385 treatment of the same PDX cell line in vitro showed no impact on cell viability or proliferation, suggesting that the survival advantage mediated by PT2385 may be linked to inhibition of tumor aspects required for in vivo progression.”

• cites [55] sourceCould not verify

  The Results (p. 2) concern MGMT promoter methylation and survival after temozolomide and radiotherapy in patients with glioblastoma. Searches for PT2385, PDX cells, and in vitro viability or proliferation found no passage addressing the claimed experiment or its proposed explanation. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

PT2385 treatment had no effect on tumor growth, HIF target gene transcription, or chemotherapy response.

“However, treatment with PT2385 had no effect on tumor growth, did not impact transcription of HIF target genes and did not modulate chemotherapy response [43].”

• cites [43] sourceCould not verify

  The Results describe HIF1α and HIF2α shRNA knockdown in glioma stem cells, not PT2385 treatment. Searches for PT2385 and chemotherapy response found no passage assessing the drug’s effects on tumor growth, HIF target-gene transcription, or chemotherapy response. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

Other studies found elevated HIF-1α in aggressive necrotic tumors, associations between HIF-1α and MYCN-amplified NB, and causal roles for HIF-1α in etoposide resistance.

“However, other studies have reported elevated HIF-1α expression in highly aggressive and necrotic tumors, revealed associations of HIF-1α with MYCN-amplified NB, a subtype associated with poor prognosis, and reported causal roles of HIF-1α in etoposide resistance [40–42].”

• cites [40] sourcePartly supported

  The Abstract reports that hypoxia protected neuroblastoma CHP126 cells against etoposide (VP-16) cytotoxicity. Section 2.5 attributes that protection partly to p53 and ERK pathways; it does not establish a causal role for HIF-1α. The Introduction also does not establish the claimed HIF-1α associations with aggressive necrotic tumors or MYCN-amplified neuroblastoma. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [41] sourceNot checked — no full text of the source
• cites [42] sourceNot checked — no full text of the source

May combine two claims.

High HIF-2α protein in GBM correlates with shorter overall survival, while HIF-1α does not correlate with outcome.

“High levels of HIF-2α protein in GBM correlate to decreased OS, whereas HIF-1α is not correlated to outcome [45,46].”

• cites [45] sourcePartly supported

  The Introduction section, “The Role of Hypoxia Inducible Factors in Cancer Stem Cell Self-Renewal and Tumor Growth” (page unavailable), reports that HIF2α, but not HIF1α, levels were associated with negative survival in a patient database. However, that analysis measured mRNA, not protein, so it does not establish the claimed protein-level correlation. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [46] sourceNot checked — no full text of the source

May combine two claims.

In NB specimens, HIF-1α expression negatively correlates with blood vessel presence, indicating HIF-1α is expressed only in hypoxic cells.

“In NB clinical specimens, HIF-1α expression negatively correlates with the presence of blood vessels indicating that HIF-1α is expressed exclusively in hypoxic cells [43].”

• cites [43] sourcePartly supported

  The Results section on HIF expression in glioma stem cells reports HIF-1α staining near regions of necrosis in human glioblastoma specimens and increased expression under severe hypoxia. It does not study NB clinical specimens, report a negative correlation with blood-vessel presence, or establish that HIF-1α is expressed exclusively in hypoxic cells. No page number is available in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

Chromosome 14q loss spanning HIF1A is frequent in RCC, but recent work suggests HIF1A may not be the deletion target, challenging HIF-1α's tumor suppressor role.

“Furthermore, although loss of chromosome 14q spanning the HIF1A locus occurs frequently in RCC, recent studies suggest that HIF1A may not be the target of 14q deletion, challenging the notion of HIF-1α as a tumor suppressor in ccRCC [30,31].”

• cites [30] sourceCould not verify

  The Results section on molecular similarities reports HIF-1α expression in mouse and human ccRCC, but does not discuss chromosome 14q or whether HIF1A is a deletion target. Searches for HIF1A, 14q deletion, and HIF-1α as a tumor suppressor found no passage in our copy that addresses the attributed claim; page numbers were unavailable. (LLM, conf=0.72)

  Experimental — accuracy not yet measured
• cites [31] sourcePartly supported

  The Results section on the immune microenvironment reports frequent HIF1A copy loss in ccRCC, and the Discussion challenges a simple HIF-1α tumour-suppressor model. But the paper does not suggest that HIF1A is not a target of 14q deletion; its Results instead suggest that loss of one HIF1A allele may be selected for during tumour evolution. Page numbers are unavailable in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

HIF-2α is found in dense perivascular cell clusters with a neural crest-like, HIF-1α-negative phenotype, suggesting these cells are not hypoxic.

“However, HIF-2α is located in dense clusters of cells adjacent to blood vessels, referred to as the perivascular niche, which have a neural crest-like phenotype, and are HIF-1α negative, suggesting they are not hypoxic [43].”

• cites [43] sourcePartly supported

  The Results section (page unavailable) reports HIF-2α-positive cells around proliferating blood vessels, supporting the perivascular location. It does not describe those cells as dense clusters with a neural crest-like phenotype or establish that they are HIF-1α-negative. The Discussion (page unavailable) cautions that tumor vasculature can be poorly functional and associated with hypoxia, so proximity to a vessel does not establish that the cells are not hypoxic. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

In that model, HIF-1α deletion prevented tumor formation, while HIF-2α deletion only moderately affected tumor onset.

“In this model, HIF-1α deletion abrogated tumor formation whereas HIF-2α deletion had only moderate effects on tumor onset [33].”

• cites [33] sourceCould not verify

  The Introduction (page unavailable) discusses HIF1A deletion in high-grade kidney tumors and HIF-1α expression in early lesions, but does not describe the claimed deletion experiment. Searches for tumor formation, tumor onset, and HIF-1α/HIF-2α knockout found no passage comparing their effects in that model. (LLM, conf=0.72)

  Experimental — accuracy not yet measured

May combine two claims.

Those studies used 786-0 cells, which are pVHL-deficient RCC cells lacking HIF-1α, and may have adapted to depend selectively on HIF-2α.

“However, these studies were performed using 786–0 cells, which are pVHL deficient RCC cells that intrinsically lack HIF-1α expression, and may have thus adapted to selectively depend on HIF-2α [26–28].”

• cites [26] sourceNot checked — no full text of the source
• cites [27] sourcePartly supported

  The supplied Abstract passages identify 786-O as VHL-deficient ccRCC cells lacking wild-type HIF-1α and show HIF-2α-dependent growth. But the paper also studied other cell lines and explicitly says HIF-2α dependence is not linked to HIF-1α status; it does not support the proposed adaptation from HIF-1α loss. Page numbers were not supplied. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [28] sourcePartly supported

  The Results section ('Frequent Homozygous Deletions of the HIF1α Locus') identifies 786-O as a renal carcinoma line that lacks detectable wild-type HIF1α while producing HIF2α; it also reports an aberrant HIF1α protein, so 'lacking HIF-1α expression' needs that qualification. The Introduction describes HIF2α as a driver in pVHL-defective renal carcinomas, but the paper does not say that 786-O cells adapted to depend selectively on HIF2α, or establish that the cited studies all used 786-O cells. Page numbers were not available in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

PT2385 increased survival in an orthotopic GBM PDX model without significant differences in tumor size by bioluminescent imaging.

“Indeed, selective HIF-2α inhibition using PT2385 increased animal survival in an orthotropic GBM PDX model although no significant differences in tumor size (detected by bioluminescent imaging) was observed [55].”

• cites [55] sourceCould not verify

  The Results (pp. 2, 4) report survival outcomes in patients treated with temozolomide and radiotherapy, not animals treated with PT2385. Searches for PT2385, HIF-2α, patient-derived xenografts, and bioluminescent imaging found no passage addressing the claimed experiment. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

The initial proposal that HIF-2α is pro-tumorigenic came from studies where HIF-2α overexpression, but not HIF-1α, blocked pVHL re-expression from inhibiting xenograft formation, and HIF-2α shRNA prevented xenograft formation.

“Specifically, the pro-tumorigenic role of HIF-2α was initially proposed based on studies showing that overexpression of HIF-2α, but not HIF-1α, abrogated the ability of pVHL re-expression to inhibit xenograft formation, and the converse that HIF-2α shRNA prevented tumor xenograft formation [26–28].”

• cites [26] sourceNot checked — no full text of the source
• cites [27] sourcePartly supported

  The paper’s main text (indexed under Abstract; page unavailable) says that inhibiting A498 tumors was consistent with earlier effects of HIF-2α shRNAs, supporting the claim’s general point that HIF-2α promotes tumor growth. It does not state that shRNA prevented xenograft formation or describe the claimed comparison in which HIF-2α, but not HIF-1α, overexpression overcame inhibition by pVHL re-expression. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [28] sourcePartly supported

  The Introduction (page unavailable) reports that HIF-2α, but not HIF-1α, can override pVHL’s tumor-suppressor activity and that eliminating HIF-2α suppresses tumor formation in preclinical models. It does not specify HIF-2α overexpression, pVHL re-expression, HIF-2α shRNA, or xenograft formation as the experiments behind those findings. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

CD44 cleavage in GBM stem-like cells releases CD44ID, which binds HIF-2α but not HIF-1α, protects it from oxygen-dependent degradation, and enhances HIF-2α transcriptional activity via CBP/p300.

“Intriguingly, cleavage of CD44 in GBM stem-like cells releases an intracellular domain (CD44ID) that binds to HIF-2α, but not HIF-1α, and protects it from degradation in the presence of oxygen. This enhances HIF-2α transcriptional activity in a CBP/p300 dependent manner [53].”

• cites [53] sourceCould not verify

  The Results section on HIF2α in glioma cell culture reports increased HIF2α expression under hypoxia, and the Discussion addresses HIF2α inhibition with PT2385. Neither addresses CD44 cleavage, CD44ID binding, protection from oxygen-dependent degradation, or CBP/p300-dependent transcriptional activity; searches for CD44 and those mechanisms found no supporting passage in our copy. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Because HIF-2α is strongly expressed in NB tumor cell cytoplasm at physiological oxygen (5% O2), this may indicate additional cytoplasmic functions for HIF-2α independent of HIF-1β-dependent transcription, such as mRNA translation regulation.

“Since HIF-2α is strongly expressed in the cytoplasm of NB tumor cells at physiological oxygen levels (5% O2), this could suggest additional largely unexplored functions of HIF-2α in the cytoplasm, independent of HIF-1β-dependent transcription, such as regulation of mRNA translation [9,43].”

• cites [9] sourceNot checked — no full text of the source
• cites [43] sourcePartly supported

  Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

SOD3 overexpression in endothelial cells stabilizes HIF-2α but not HIF-1α, enhances T cell tumor infiltration via a HIF-2α-WNT pathway, and improves adoptively transferred tumor-specific CD8+ T cell effectiveness in a syngeneic mouse lung cancer model.

“There is also evidence of extensive crosstalk between the immune and non-immune components of the TME, whereby superoxide dismutase (SOD3) overexpression in endothelial cells (EC), which stabilizes HIF-2α but not HIF-1α, enhances T cell tumor infiltration in a HIF-2α-WNT pathway dependent manner, improving the effectiveness of adoptively transferred tumor-specific CD8+ T cells in a syngeneic mouse”

• cites [86] sourceCould not verify

  Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

Hypoxia can abolish NK cell killing activity, correlating with increased HIF-1α.

“Hypoxia can abolish the cell killing activity of NK cells, which correlates with an increase in HIF-1α [78].”

• cites [78] sourcePartly supported

  The Results section, “HIF-1α regulates MDSC differentiation and function” (page unavailable), reports that hypoxia substantially increased HIF-1α in myeloid-derived suppressor cells. The cited paper does not report that hypoxia abolishes NK-cell killing activity or link that activity to HIF-1α; its functional experiments concern MDSCs and T-cell suppression. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

Myeloid-specific HIF-1α overexpression produces hyperinflammatory, M1-polarized macrophages with increased glycolysis, suggesting a link between HIF-1α and M1 polarization.

“Conversely, myeloid-specific overexpression of HIF-1α results in hyperinflammatory, M1-polarized macrophages associated with increased glycolysis, suggesting a link between HIF-1α and M1-polarization [63].”

• cites [63] sourceCould not verify

  The cited review’s PD1/PDL1 biological function section discusses glucose uptake in T cells, and its adoptive T cell transfer section discusses macrophage-mediated inflammation. Neither passage addresses myeloid-specific HIF-1α overexpression, M1 polarization, or increased macrophage glycolysis. Searches for those terms and HIF-1α found no passage supporting the attributed claim. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

Myeloid-specific HIF-1α deletion causes defective glycolysis and ATP generation, impairing myeloid cell motility and function.

“Myeloid-specific HIF-1α deletion results in defective glycolysis and ATP generation, leading to impairment of myeloid cell motility and function (Fig. 2B) [61,62].”

• cites [61] sourcePartly supported

  The Introduction (page not provided) says HIF1 regulates cellular ATP concentration and myeloid-cell functions including motility. The Discussion reports impaired glycolysis in HIF1α-deficient mice, but the paper’s own experiment used myeloid-specific HIF1α overexpression, not deletion (Methods §2.2; Results §3.2). It does not establish that myeloid-specific deletion caused the claimed sequence of defective glycolysis, reduced ATP generation, and impaired motility and function. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [62] sourcePartly supported

  The migration-and-invasion section reports ATP depletion in HIF-1α-deficient macrophages, and the discussion reports reduced migration, inflammation, and bacterial killing after macrophage HIF-1α loss. It also cites a role for HIF-1α in glycolysis in hypoxic cells. But the discussion explicitly says it is unclear how much of the functional impairment results from reduced ATP, so the claim’s causal link is stronger than this source supports. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Inhibition of ENTPD2 significantly decreased tumor growth and potentiated ICB effects.

“Inhibition of ENTPD2 significantly decreased tumor growth and potentiated the effects of ICBs, suggesting the inhibition of MDSCs as a potential therapeutic strategy to increase the efficacy of ICB.”

• cites [84] sourceCould not verify

  The Results section reports that SOD3 expression improved the effect of adoptively transferred T cells on tumor growth. Neither those passages nor searches for ENTPD2, MDSCs, and immune checkpoint blockade found a passage about ENTPD2 inhibition reducing tumor growth or potentiating ICB; no page numbers are available in our copy. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

MICA is the ligand for NKG2D, an activating receptor that promotes tumor elimination by NK and CD8+ T cells.

“MICA is the ligand for Natural killer group 2 member D (NKG2D), the activating receptor that promotes tumor elimination by NK and CD8+ T cells.”

• cites [83] sourcePartly supported

  In “Effect of hypoxia on effector cells” (page unavailable), the paper identifies MICA as an NKG2D ligand and calls NKG2D an activating receptor on NK and T cells; it also links reduced NKG2D function to impaired tumor-cell killing. It does not specifically identify the NKG2D-expressing T cells as CD8+ T cells, so that part of the claim is not established by the passage. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Hypoxia promotes HIF-1α-dependent CCL28 secretion by tumor cells, recruiting CCR10+ T reg cells, suppressing cytotoxic T cells and promoting tumor growth.

“For example, hypoxia promotes the secretion of CCL28 by tumor cells in a HIF-1α-dependent manner, which enhances recruitment of CCR10+ T reg cells to the tumor site, suppressing the functions of cytotoxic T cells and promoting tumor growth (Fig. 2C) [81,82].”

• cites [81] sourceCould not verify

  The Background (page unavailable) discusses tumor immune evasion through MICA shedding, not hypoxia-induced CCL28 secretion. Searches for HIF-1α, CCL28, and CCR10+ regulatory T-cell recruitment found no passage addressing the claimed pathway. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [82] sourcePartly supported

  The Introduction (page not available) says that HIFs promote Treg infiltration through CCL28 in an ovarian cancer model, supporting the central recruitment mechanism. It does not specify HIF-1α-dependent CCL28 secretion by tumor cells or CCR10+ Tregs, nor does it link that pathway to cytotoxic T-cell suppression or tumor growth. The Discussion describes immune suppression and tumor growth in the paper’s separate MDSC pathway. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Bortezomib inhibits p300 recruitment and blocks PI3K/Akt/TOR, inhibiting HIF-1α synthesis and activation at multiple levels without affecting HIF-2α.

“Bortezomib, a proteasome inhibitor, inhibits the recruitment of p300 and blocks the PI3K/Akt/TOR pathway, which inhibits HIF-1α synthesis and activation at multiple levels, but does not affect HIF-2α [24,90].”

• cites [24] sourceNot checked — no full text of the source
• cites [90] sourceCould not verify

  The Results sections on HIF-1/2α and HILPDA discuss ferroptosis sensitivity, not bortezomib’s effects on HIF signaling (page unavailable). Searches for bortezomib, p300 recruitment, PI3K/Akt/TOR, and selective inhibition of HIF-1α found no passage addressing the claim. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

In follicular thyroid cancer, loss of HIF-1α reduces PD-L1 expression on tumor cells and reduces tumor growth.

“In follicular thyroid cancer, loss of HIF-1α reduces PD-L1 expression on tumor cells, resulting in reduced tumor growth, and in glioma, expression of PD-L1 strongly correlated with HIF-1α levels, and high PD-L1 was associated with worse outcome [71,72].”

• cites [71] sourceNot checked — no full text of the source
• cites [72] sourcePartly supported

  The Results and discussion (page unavailable) report reduced growth of HIF-1α (Del) B16-F10 melanoma tumors in mice, supporting the growth finding only in a different cancer. The Introduction discusses PD-L1 on myeloid-derived suppressor cells, not reduced PD-L1 on thyroid tumor cells; the copy does not establish the claimed PD-L1-mediated mechanism in follicular thyroid cancer (searched: thyroid, PD-L1 expression on tumor cells). (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

HIF-1α upregulates ADAM10 in tumor cells, promoting MICA shedding from the tumor cell surface.

“In addition, HIF-1α upregulates a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) in tumor cells, which promotes the shedding of Major histocompatibility complex class I chain related molecule (MICA) from the surface of tumor cells.”

• cites [83] sourceCould not verify

  The sections on hypoxia signaling and hypoxia-driven immune-checkpoint changes discuss HIF-1α regulation of other targets, but not ADAM10 or MICA shedding. Searches of our copy for ADAM10, MICA, and the proposed shedding mechanism found no passage addressing that link; MICA appears only in a reference title. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

MDSCs have immunosuppressive activities that inhibit cytotoxic CD8+ T and NK cells, suppress dendritic cells, and activate Tregs, enabling cancer cells to escape immunosurveillance and resist ICB.

“Myeloid-derived suppressor cells (MDSCs), a heterogeneous population of immature myeloid cells that expands in cancer, possess immunosuppressive activities that inhibit cytotoxic CD8+ T and NK cells, suppress antigen-presenting dendritic cells, and activate Tregs, allowing cancer cells to escape immunosurveillance and develop resistance to ICB [79].”

• cites [79] sourceCould not verify

  The Introduction and Discussion describe CCL28-mediated recruitment of Tregs in liver cancer and possible suppression of antitumor responses, but do not attribute those effects to MDSCs. Searches for MDSC effects on CD8+ T cells, NK cells, dendritic cells and Tregs, and for ICB resistance found no supporting passage in the paper's text; MDSCs appear only in a reference title. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

Hypoxia-induced HIF-1α, but not HIF-2α, in HCC cells induces ENTPD2, increasing MDSC infiltration and promoting growth of syngeneic Hepa1-6 HCC tumors in mice.

“Finally, hypoxia-induced HIF-1α (but not HIF-2α) in hepatocellular carcinoma (HCC) cells induces Ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2) expression, which increases MDSC infiltration into the tumor mass, promotes the growth of syngeneic Hepa1–6 HCC tumors in mice [84].”

• cites [84] sourceCould not verify

  The Results section on SOD3–HIF-2α and T-cell transmigration describes endothelial HIF-2α and T-cell infiltration in EG7 and LLC tumors, not the proposed mechanism in HCC cells. Searches for ENTPD2, MDSCs, and Hepa1-6 found no passage addressing the claim; the different finding is not a contradiction. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

Myeloid-specific HIF-2α deletion causes defects in inflammatory cytokine/chemokine production but does not alter ATP production, unlike HIF-1α deletion.

“In contrast, myeloid-specific HIF-2α deletion causes defects in the production of inflammatory cytokines/chemokines, but unlike HIF-1α deletion, does not show altered ATP production, suggesting non redundant roles of the HIF transcription factors in TAMs [64].”

• cites [64] sourceCould not verify

  Section 4 discusses HIF-dependent tumor metastasis, and Section 5 discusses extracellular ATP after chemotherapy, but neither addresses myeloid-specific HIF deletion. Searches for HIF-2α, myeloid-specific deletion, cytokine or chemokine production, and ATP production found no passage comparing HIF-2α with HIF-1α on these outcomes. (LLM, conf=0.73)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

HIF transcription factors are important in embryonic development and adulthood, including wound healing after ischemia-reperfusion and resolution of inflammation.

“The HIF transcription factors play critical roles during embryonic development and in the adult, they are essential for regulating the wound healing response during ischemia-reperfusion injury and in the resolution of inflammation [2].”

• cites [2] sourceNot checked — no full text of the source

May combine two claims.

HIF-1α is expressed widely in hypoxic tissues, while HIF-2α appears in fewer cell types, including endothelial cells and macrophages, often under both low and normal oxygen.

“HIF-1α is ubiquitously expressed in hypoxic tissues, whereas HIF-2α is detected in a more restricted set of cell types, including vascular endothelial cells and macrophages, where it is frequently expressed under both hypoxic and non-hypoxic conditions.”

• cites [2] sourceNot checked — no full text of the source
• cites [8] sourceNot checked — no full text of the source

May combine two claims.

HIF-1α and HIF-2α have distinct, frequently opposing functions.

“The best characterized HIF isoforms, HIF-1α and HIF-2α, despite their considerable similarities, show non-overlapping and often antagonistic roles, in part due to their unique regulators, gene targets and differential expression patterns [2,8] (Fig. 2A).”

• cites [2] sourceNot checked — no full text of the source
• cites [8] sourceNot checked — no full text of the source

May combine two claims.

HIF activation in cancer increases metastatic potential and contributes to resistance to chemotherapy and radiotherapy.

“HIF activation in cancer enhances metastatic potential and contributes to resistance to chemo- and radiotherapy [5].”

• cites [5] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Kidney cancer, neuroblastoma, and glioblastoma are the best-known examples of HIF-α isoform specificity.

“The best-known examples of HIF-α isoform specificity are seen in kidney cancer, neuroblastoma and glioblastoma, described in further detail below.”

May combine two claims.

Most solid tumors are hypoxic because their growth exceeds oxygen supply, worsened by poor perfusion from abnormal tumor blood vessels.

“In cancer, the majority of solid tumors are hypoxic due to their rapid growth that outstrips their oxygen supply, exacerbated by the reduced perfusion caused by the aberrant tumor vasculature [4].”

• cites [4] sourceNot checked — no full text of the source

May combine two claims.

Genetic and functional studies support HIF-2α as pro-tumorigenic and HIF-1α as tumor suppressive in ccRCC, which led to HIF-2α-specific inhibitor development.

“Genetic and functional studies have supported a pro-tumorigenic role of HIF-2α, and a tumor suppressor role for HIF-1α in ccRCC, which has prompted the development of HIF-2α specific inhibitors [17].”

• cites [17] sourceNot checked — no full text of the source

May combine two claims.

HIF-1α and HIF-2α have different timing and oxygen sensitivities: HIF-1α responds quickly to severe hypoxia (1-2% O2), while HIF-2α accumulates gradually in prolonged moderate hypoxia (<5% O2).

“The HIF transcription factors show disparate spatiotemporal regulation, with HIF-1α being activated rapidly during acute, severe hypoxia (1–2% O2), and HIF-2α gradually accumulating during prolonged, more moderate hypoxia (< 5% O2) [2,9].”

• cites [2] sourceNot checked — no full text of the source
• cites [9] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Factor inhibiting HIF hydroxylates asparagine residues in the HIF-α C-terminal domain, preventing its interaction with CBP/p300.

“Transcriptional activation of HIF-α is further inhibited in the presence of oxygen by Factor inhibiting HIF (FIH), which hydroxylates asparagine residues within the C-terminal domain of HIFα, blocking their interaction with transcriptional co-activators CREB-binding protein (CBP)/p300 [2].”

• cites [2] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The HIF transcription factors consist of one of three oxygen-sensitive HIF-α subunits (HIF-1α, HIF-2α, HIF-3α) plus a constitutive HIF-1β subunit, and HIF-1α and HIF-2α are the most studied.

“They comprise of one of three major oxygen labile HIF-α subunits (HIF-1α, HIF-2α and HIF-3α), and a constitutive HIF-1β subunit (also known as ARNT), with HIF-1α and HIF-2α being the best studied [1].”

• cites [1] sourceNot checked — no full text of the source

May combine two claims.

HIF-1α is thought to be important in ccRCC initiation and is elevated in the earliest pre-neoplastic lesions of VHL patients.

“However, HIF-1α is believed to play an important role during ccRCC initiation, and is elevated in the earliest pre-neoplastic lesions in VHL patients [21].”

• cites [21] sourceNot checked — no full text of the source

May combine two claims.

HIF activation alters gene expression in both malignant and immune cells of the tumor microenvironment, thereby affecting tumor growth and response to therapy.

“This leads to activation of the hypoxia-inducible factor (HIF) family of transcription factors, which modulate gene expression within both tumor cells and immune cells within the tumor microenvironment, influencing tumor progression and treatment response.”

• AssumptionRests on an assumption: Hypoxia is a hallmark of all solid tumors and their metastases.
• AssumptionRests on an assumption: HIFs are the master regulators of the hypoxia response.

May combine two claims.

A Phase II trial of PT2385 in recurrent GBM found no radiographic responses, though high systemic exposure was associated with longer progression-free survival, possibly due to drug exposure variation.

“However, a Phase II clinical trial of PT2385 for treatment of recurrent GBM found no radiographic responses, although this may have been caused by variations in drug exposure as patients with high systemic exposure had longer progression free survival (PFS) [56].”

• cites [56] sourceNot checked — no full text of the source

May combine two claims.

HIF-2α marks immature neural crest- and mesenchymal-like neuroblastoma cells in the perivascular niche, which are associated with metastatic disease and poor clinical outcome.

“In this regard, HIF-2α serves as a marker of immature, neural crest- and mesenchymal-like neuroblastoma cells within the perivascular niche, which are associated with metastatic disease and poor clinical outcome, suggesting that the selective targeting HIF-2α could be a potential therapeutic strategy [9].”

• cites [9] sourceNot checked — no full text of the source

May combine two claims.

A study of tissue from 380 patients found high HIF-2α significantly associated with longer overall survival, while high HIF-1α was significantly associated with higher-grade tumors and shorter overall survival in univariable and multivariable analyses.

“A recent study using tissue from 380 patients revealed a significant association of high HIF-2α with increased overall survival (OS), whereas high HIF-1α was significantly associated with higher-grade tumors and reduced OS in both the univariable and multivariable setting [35].”

• cites [35]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Belzutifan (PT2977) showed promising single-agent activity in heavily pretreated advanced ccRCC and in VHL-associated non-metastatic ccRCC, and the FDA approved it for cancers associated with VHL disease.

“PT2977 (also known as MK-6482, Belzutifan), a PT2385 derivative with improved pharmacokinetic profile and potency, demonstrated promising single-agent activity in heavily pre-treated patients with advanced ccRCC, and in VHL-associated non-metastatic ccRCC, and was recently approved by the FDA for the treatment of cancers associated with VHL disease [23,24] [25].”

• cites [23] sourceNot checked — no full text of the source
• cites [24] sourceNot checked — no full text of the source
• cites [25] sourceNot checked — no full text of the source

May combine two claims.

Hypoxic gene expression profiles predict poor prognosis in NB, and hypoxia can promote NB development and progression by inducing dedifferentiation and genes for survival, proliferation, and metastasis.

“Hypoxic gene expression profiles in NB are predictors of poor prognosis, and hypoxia can contribute to NB development and progression by promoting dedifferentiation of tumor cells, and inducing genes involved in cell survival, proliferation, and metastasis [37,38].”

• cites [37] sourceNot checked — no full text of the source
• cites [38] sourceNot checked — no full text of the source

May combine two claims.

Several IHC studies found high HIF-1α correlated with low tumor stage and better prognosis, while HIF-2α correlated with unfavorable prognosis and high tumor stage.

“Several IHC-based studies have identified a correlation between high HIF-1α and low tumor stage, and a more favorable prognosis, whereas HIF-2α was correlated to unfavorable prognosis and high tumor stage [39].”

• cites [39] sourceNot checked — no full text of the source

May combine two claims.

HIF-1α was mainly expressed in tumor-associated macrophages, suggesting that non-neoplastic tumor microenvironment components may influence patient outcome.

“HIF-1α was primarily expressed in tumor-associated macrophages (TAMs) underscoring the potential involvement of other non-neoplastic components of the TME to patient outcome.”

• cites [35]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Tumor cells evade cytotoxic T cells through defective antigen presentation and immune suppressive mediators.

“Tumor cells employ a variety of strategies including defective antigen presentation and production of immune suppressive mediators to evade the tumor killing properties of cytotoxic T cells [66].”

• cites [66] sourceNot checked — no full text of the source

May combine two claims.

Hypoxia promotes an M2 phenotype in TAMs, enhancing tumor angiogenesis, proliferation and invasion.

“Hypoxia, which evokes a wound healing response in normal physiology, promotes an M2 phenotype in TAMs, which leads to enhanced tumor angiogenesis, proliferation and invasion [60].”

• cites [60] sourceNot checked — no full text of the source

May combine two claims.

Single-cell RNA sequencing studies reveal heterogeneity, plasticity and interconnectivity among cells of the TME.

“These studies show the startling heterogeneity, plasticity and interconnectivity of the cells that comprise the TME [58].”

• cites [58] sourceNot checked — no full text of the source

May combine two claims.

HIF-1α expression in NK cells can promote tumor growth by inhibiting NK activation or stimulating angiogenesis.

“Indeed, HIF-1α expression in NK cells can contribute to tumor growth either by inhibiting NK cell activation or by stimulating productive angiogenesis (Table 1).”

May combine two claims.

Hypoxia, via HIF-1α, converts MDSCs into antigen-nonspecific suppressors of T cell function and promotes their differentiation into immune-suppressive TAMs.

“Hypoxia, through HIF-1α, drives the conversion of MDSCs into antigen-nonspecific suppressors of T cell function and promotes the differentiation of MDSCs into immune-suppressive TAMs, further potentiating the immune-suppressive network [80].”

• cites [80] sourceNot checked — no full text of the source

May combine two claims.

HIF isoforms have non-overlapping contributions to TAM-tumor cell interaction, with roles varying by cellular context and microenvironmental cues.

“Taken together, these studies highlight the non-overlapping contributions of the HIF isoforms to TAM-tumor cell interaction and suggest heterogeneity in their roles depending on cellular context and micro-environmental cues.”

May combine two claims.

MDSCs contribute to angiogenesis and ECM remodeling to facilitate tumor progression.

“MDSCs also contribute to angiogenesis and remodeling of the ECM to facilitate tumor progression.”

May combine two claims.

ICB against PD-1, PD-L1, or CTLA4 reactivates T cells and promotes anti-tumor cytotoxicity.

“Inhibition of immune checkpoints such as programmed death 1 (PD-1), its ligand programmed death 1 ligand 1 (PD-L1), or cytotoxic T-lymphocyte associated protein 4 (CTLA4) using ICB leads to T cell re-activation and anti-tumor cytotoxicity [67].”

• cites [67] sourceNot checked — no full text of the source

May combine two claims.

Hypoxia and HIF transcription factors regulate multiple aspects of the TME that affect tumor metabolism and aggressiveness and foster an immunosuppressive, tumor-permissive niche.

“hypoxia and the HIF family of transcription factors regulate diverse aspects of the TME that influence tumor metabolism and aggressiveness, and contribute to an immunosuppressive, tumor-permissive niche.”

May combine two claims.

No pharmacological agents specifically targeting HIF-1α have been described, unlike HIF-2α, though compounds targeting HIF-1α mRNA expression, protein synthesis/stabilization and dimerization exist.

“Unlike HIF-2α, no pharmacological agents that specifically target HIF-1α have been described, although a number of compounds which target HIF-1α mRNA expression, protein synthesis/stabilization and dimerization, have been identified [87].”

• cites [87]Not checked — no full text of the source

May combine two claims.

HIF-1/2α and PD-L1 expression are closely linked, suggesting HIF-α inhibition could enhance PD-1/PD-L1 inhibitor therapy.

“Thus, the expression of HIF-1/2α and PD-L1 are closely linked, suggesting that HIF-α inhibition could enhance the efficacy of PD-1/PD-L1 inhibitor therapy.”

May combine two claims.

Both HIF-1 and HIF-2 contribute to angiogenesis and a tumor permissive TME.

“whereas both contribute to angiogenesis and the generation of a tumor permissive TME.”

May combine two claims.

Belzutifan showed significant efficacy in VHL disease-related renal cell carcinomas, hemangioblastomas, and pancreatic neuroendocrine tumors, and received FDA approval for VHL-disease-related cancers in August 2021.

“The most advanced of these inhibitors to date, Belzutifan demonstrated significant efficacy in VHL disease-related renal cell carcinomas, hemangioblastomas, and pancreatic neuroendocrine tumors, and received FDA approval for the treatment of patients with VHL-disease-related cancers in August 2021 [25].”

• cites [25] sourceNot checked — no full text of the source